Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma

J Dermatol. 2020 Jun;47(6):e235-e237. doi: 10.1111/1346-8138.15336. Epub 2020 Apr 10.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Blood Coagulation / drug effects
  • Blood Coagulation / immunology
  • Disseminated Intravascular Coagulation / chemically induced
  • Disseminated Intravascular Coagulation / diagnosis*
  • Disseminated Intravascular Coagulation / drug therapy
  • Disseminated Intravascular Coagulation / immunology
  • Drug Therapy, Combination / methods
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects*
  • Ipilimumab / adverse effects*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / secondary
  • Lung Neoplasms / therapy
  • Lymphocyte Activation / drug effects
  • Male
  • Melanoma / immunology
  • Melanoma / secondary
  • Melanoma / therapy
  • Middle Aged
  • Nivolumab / adverse effects*
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology

Substances

  • Immune Checkpoint Inhibitors
  • Ipilimumab
  • Nivolumab